eprintid: 570
rev_number: 11
eprint_status: archive
userid: 4
dir: disk0/00/00/05/70
datestamp: 2022-05-12 21:10:38
lastmod: 2024-03-14 21:26:25
status_changed: 2022-05-12 21:10:38
type: article
metadata_visibility: show
creators_name: IBADOV, Ravshan Aliyevich
creators_name: ARIFJANOV, Anvar Shamkhatovich
creators_name: IBRAGIMOV, Sardor Khamdamovich
creators_name: KHAKIMOV, Begali Bobokulovich
creators_id: dr.sardor.ibragimov@gmail.com
title: Dexmedetomidine for sedation and correction of psychoemotional disorders in critically ill patients with COVID-19
ispublished: pub
subjects: Q1
subjects: R1
divisions: j8
full_text_status: public
keywords: COVID-19,  Intensive care unit, Depression, Anxiety, Posttraumatic stress Disorder, Sedation, Dexmedetomidine, Comparison study
abstract: Aim. The objective of this study was to evaluate sedation therapy effectiveness in critically ill patients with severe COVID-19 who received dexmedetomidine compared to propofol. Methods. The research was done in a prospective single center to a cohort study of critically ill 333 adult patients with COVID-19 and psychoemotional disorders (depression, anxiety and posttraumatic stress disorder) admitted in the ICU of the Republican Specialized Hospital for COVID-19 in Uzbekistan. Patients were non-invasive ventilated more than 24 hours and received intravenous sedation with dexmedetomidine or propofol. Results. The risk of progression of the pathological process decreased from 47.6% to 21.8% and, accordingly, the proportion of patients with stabilization and improvement of their condition increased from 52.4% to 79.4% (p<0.001). The possibilities of non-invasive respiratory support were expanded with a reduction in the frequency of tracheal intubations from 17.3% to 7.3% (p<0.001), the duration of ICU stay was from 12.6±0.8 to 9.4±0.6 days, and the duration of respiratory therapy was from 8.4±0.5 to 5.2±0.4 days. In particular, there was an improvement in oxygen saturation (SpO2) recovery after one day of intensive therapy from 86.6±0.2% to 92.2±0.3% with non-invasive ventilation and a higher oxygenation index (2.3 in the dexmedetomidine group versus 1.6 in the propofol group, p=0.032) during the period of sedation withdrawal. Conclusion. In the presence of severe psychoemotional disorders, the effectiveness of etiotropic and pathogenetic treatment protocols of COVID-19 directly depends on the proper sedation regimen. In this aspect, dexmedetomidine provides adequate and safe respiratory support with an improvement in external respiration, blood gas composition and a minimal negative hemodynamic effect.
date: 2021-09-25
publication: Journal of Life Science and Biomedicine
volume: 11
number: 05
publisher: Scienceline Publications, Ltd
pagerange: 80-87
id_number: https://dx.doi.org/10.51145/jlsb.2021.10
refereed: TRUE
issn: 2251-9939
official_url: https://jlsb.science-line.com/attachments/article/87/JLSB%2011(5)%2080-87,%202021-Dexmedetomidine%20for%20psychoemotional%20disorders%20in%20COVID-19%20patients.pdf
j_index: notindex
citation:    (2021)     Dexmedetomidine for sedation and correction of psychoemotional disorders in critically ill patients with COVID-19.   Journal of Life Science and Biomedicine.  pp. 80-87.  ISSN 2251-9939   
document_url: http://eprints.science-line.com/id/eprint/570/1/JLSB%2011%285%29%2080-87%2C%202021-Dexmedetomidine%20for%20psychoemotional%20disorders%20in%20COVID-19%20patients.pdf